Axel Müller
Interim Chief Executive Officer,
business
m2p-labs
Germany
Biography
Dr. Axel Müller serves as Interim Chief Executive Officer at Aenova Group GmbH. He served as the Chief Executive Officer of SkyePharma plc., since August 23, 2010. Dr. Müller served as Chief Executive Officer of Acino Holding AG, Switzerland, from June 2008 to March 2010, having joined Acino in 2005 as Chief Executive Officer of the CIMEX business unit. Prior to that he served as President of Siegfried Generics (part of Siegfried AG, Switzerland) from 2004 to 2005, and Managing Director and Vice President International of Aceto Holding GmbH, Germany, which he joined in 2001 through its acquisition of Schweizerhall Pharma, Switzerland, where he served as President since 1998. He served as Head of Life Sciences practice at management consultants Arthur D. Little, and a number of R&D and marketing and sales roles at Novartis. He served as Executive Director of SkyePharma plc. Dr. Müller is a German citizen with a PhD in Pharmacology from Tübingen University.
Research Interest
business
